Moderna Inc. (NASDAQ:MRNA) stock is trading lower on Wednesday after the company added a Chief Operating Officer role to support the increasing scale and diversification.
Executive Leadership Update The new role comes as Moderna prepares for the potential launch and scale-up of intismeran autogene following positive Phase 3 results and continues to advance a broader oncology portfolio. Juan Andres will return to Moderna as COO, effective October 5.
Moderna also announced that Jerh Collins, Chief Technical Operations and Quality Officer, has decided to retire. S.
FDA approval of Moderna’s seasonal flu vaccine and the European Commission marketing authorization of the company’s seasonal flu plus COVID combination vaccine. Individualized Cancer Therapy The company’s stock gained massive momentum when Merck & Co Inc.
(NYSE:MRK) and Moderna shared topline data from individualized cancer therapy for advanced skin cancer. The company released positive topline results from the Phase 3 INTerpath-001 trial of adjuvant treatment with intismeran autogene (intismeran; V940 or mRNA-4157) combined with Keytruda (pembrolizumab), in patients with completely resected stage IIB-IV melanoma.
Intismeran autogene is an mRNA-based individualized neoantigen therapy (INT) designed for each patient based on the unique mutations in their tumor, training and activating the immune system to recognize and fight cancer. S.
1-lineage XFG subvariant of SARS-CoV-2 for COVID-19. The updated formula for Spikevax is now approved for individuals 6 months through 64 years of age with at least one underlying condition placing them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older.
mNEXSPIKE, Moderna’s latest COVID-19 vaccine, is approved for individuals 12 through 64 years of age with at least one underlying condition that puts them at high risk for severe outcomes from COVID-19, and all adults 65 years of age and older. 70 at the time of publication on Wednesday, according to Benzinga Pro data.
Read Also: Is Amazon Really Facing ‘Risk Of Complete Displacement’ by Agentic Commerce?
